Granted Patent
B2
US 12,303,488 · App. 18/131,052 · Granted May 20, 2025
Cannabis based therapeutic and method of use
Assignee:
YUZU LV LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.
Claims (5)
1. A method of treating opioid addiction, the method comprising orally administering to a subject in need thereof an effective amount of a liquid pharmaceutical composition in unit dose form to treat the opioid addiction comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) and a terpene, wherein the liquid pharmaceutical composition comprises 15-20 mg of the THC per dose, and 10-12 mg of the CBD per dose and wherein the terpene is selected from the group consisting of β-myrcene, β-caryophyllene, ocimene, α-pinene, and α-humulene, wherein the subject's opioid use decreases by greater than or equal to 50% within 5 weeks of beginning treatment as determined by morphine equivalency of opioids used.
2. The method of claim 1 , wherein the liquid pharmaceutical composition is administered every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours.
3. The method of claim 1 , wherein the liquid pharmaceutical composition is administered every 6, 8, or 12 hours.
4. The method of claim 1 , wherein the liquid pharmaceutical composition further comprises a citric acid, a blue agave, a glycerine, a food coloring, or any combination thereof.
5. The method of claim 1 , wherein the method further comprises treating a pain.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 8, 2023
From: SPIRTOS, NICOLA MICHAEL
To: YUZU LV LLC
Reel/Frame 063566/0258 →
Continuity (3)
Continuation
16971781
Provisional Application
62634547
· Feb 23, 2018
References Cited (121)
US 9375417B2
· Smith et al.
· 2016
[cited by applicant]
US 20180169035A1
· Eyal
· 2018
[cited by applicant]
US 20200037638A1
· Faraci
· 2020
[cited by applicant]
CN 110575432B
· 2021
[cited by applicant]
WO 201715839A1
· 2017
[cited by applicant]
WO 201791764A1
· 2017
[cited by applicant]
WO WO2017091764
· 2017
[cited by examiner]
WO WO2017158539
· 2017
[cited by examiner]
WO WO2017158539A1
· 2017
[cited by examiner]
WO 2019034936A2
· 2019
[cited by applicant]
WO 2019165387A1
· 2019
[cited by applicant]
WO 2020006322A1
· 2020
[cited by applicant]
WO 2020009950A1
· 2020
[cited by applicant]
WO 2020021545A1
· 2020
[cited by applicant]
WO 2020214200A1
· 2020
[cited by applicant]
Russo, Frontiers in Pharmacology, Sep. 2016 | vol. 7 | Article 309, 1-19.
[cited by examiner]
Feldman, Understanding ‘Evergreening’: Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs Jun. 2022 41:6, 801-804.
[cited by examiner]
Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324-330.
[cited by examiner]
Greg Miller, Could pot help solve the U.S. opioid epidemic? Science.org/content/article/could-pot-help-solve-us-opioid-epidemic, Nov. 2016, 1-9.
[cited by examiner]
Hurd, Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage Neurotherapeutics (2015) 12:807-815.
[cited by examiner]
Reiman, Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report, Cannabis and Cannabinoid Research 2017, 2.1, 160-166.
[cited by examiner]
Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, 1986.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/040115, mailed Dec. 17, 2021.
[cited by applicant]
Li et al: Naringenin inhibits dendritic cell maturation and has therapeutic effects in a murine model of collagen-induced arthritis, Journal of Nutritional Biochemistry, 2015, vol. 26, No. 12, p. 1467-1478.
[cited by applicant]
Ruiz-Miyazawa et al.: The citrus flavanone naringenin reduces gout-induced joint pain and inflammation in mice by inhibiting the activation of NF[kappa]B and macrophage release of IL-I[beta], Journal of Functional Foods…
[cited by applicant]
Zhao et al., Naringin Protects Against Cartilage Destruction in Osteoarthritis Through Repression of NF-[kappa]B Signaling Pathway, Inflammation, 2015, vol. 39, No. 1, p. 385-392.
[cited by applicant]
Abrams Di, Couey P, Shader SB, Kelly ME, Benowitz NI. Cannabinoid-opioid Interaction in chronic pain. Clin. Pharmacol. Ther. 2011; vol. 90; pp. 844-851.
[cited by applicant]
Adams Ib, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996; vol. 91; pp. 1585-1614.
[cited by applicant]
Appendino G, Chianese G, Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr Med Chem. 2011; vol. 18; pp. 1085-1099.
[cited by applicant]
Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medicinal cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern. Med. 2014, vol. 174; pp. 1668-1673.
[cited by applicant]
Bellnier T, Brown GW, Ortega TR. Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Ment Health Clin [Internet]. 2018; vol. 8(3); pp. 110-115.
[cited by applicant]
Boehnke KF, Litinas E and Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016; vol. 17(6); pp. 739-744.
[cited by applicant]
Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. Dec. 1998; vol. 5(6 Pt B):417-431.
[cited by applicant]
Centers for Disease Control and Prevention, National Center for Injury and Prevention Control, Division of Unintentional Injury Prevention. Atlanta, Georgia. U.S. Department of Health and Human Services. “Calculating To…
[cited by applicant]
Chiarotti M, Costamagna L. Analysis of 11-nor-9-carboxy-delta (9)-tetrahydrocannabinol in biological samples by gas chromatography tandem mass spectrometry (GC/MS-MS). Forensic Scilnt. 2000; vol. 114; pp. 1-6.
[cited by applicant]
Christensen, R et al., Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet. 2007; vol. 370; pp. 1706-1713.
[cited by applicant]
Clinical Trials.gov, Identifier NCT01323569, 2013, 10 pages.
[cited by applicant]
Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007; vol. 556; pp…
[cited by applicant]
DeVries M, van Rickevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H, Pain and Nociception Neuroscience Research Group. Clin Gastroenterol Hepatol. 2017; vol. 15(7); pp. 1079-1086.
[cited by applicant]
EP Examination Report for 19710540.6 mailed Apr. 4, 2023.
[cited by applicant]
Evans F. Cannabinoids:the separation of central from peripheral effects on a structural basis. Planta Med. 1991; vol. 57; S60-S67.
[cited by applicant]
Gaoni Y and Micholaum R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish.J. Am. Chem. Soc., 1964, 86 (8), pp. 1646-1647.
[cited by applicant]
Gaskin DJ. Richard P. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research.Washington, DC: The…
[cited by applicant]
Gaskin DJ. Richard P. The Economic Costs of Pain in the United States. Journal of Pain. 2012; vol. 13(8); pp. 715-724.
[cited by applicant]
Gorzalka BB, Hill MN and Hillard CJ. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurisci Biobehav Rev. 2008; vol. 32; pp. 1152-1160.
[cited by applicant]
Goulle JP, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr. 2008; vol. 66; pp. 232-244.
[cited by applicant]
Grotenhermen F, Russo E. eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghampton, NY: The Haeworth Press, 2002.
[cited by applicant]
Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003; vol. 3(10); pp. 745-755.
[cited by applicant]
Haggerty GC, Deskin R, Kurtz PJ et al. The pharmacological activity of the fatty acid conjugate 11 palmitoyxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol. 1986; vol. 84; pp. 599-606.
[cited by applicant]
Hall W. and Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009; vol. 374; pp. 1383-1391.
[cited by applicant]
Halldin MM, Andersson LK, Widman M, Hollister LE. Further urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittel-forschung. 1982, vol. 32(9): Abstract.
[cited by applicant]
Hollister LE, Gillespie HK, Ohlsson A et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; vol. 21; pp. 171-177S.
[cited by applicant]
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.…
[cited by applicant]
Hudson BD, Hebert TE, M Kelly ME. Ligand and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor. Molecular Pharmacology 2010; vol. 77; pp. 1-9.
[cited by applicant]
Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther Drug Monit. 1998; vol. 20; pp. 570-576.
[cited by applicant]
Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992; vol. 16; pp. 276-282.
[cited by applicant]
Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005: pp. 657-690.
[cited by applicant]
Increases in Drug and Opioid Overdose Deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep. Jan. 1, 2016; vol. 64(50-51); pp. 1370-1388.
[cited by applicant]
International Search Report and Written Opinion mailed May 29, 2019.
[cited by applicant]
Verson L., Cannabis and the brain. Brain. 2003; vol. 126; pp. 1252-1270.
[cited by applicant]
Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; vol. 30; pp. 515-527.
[cited by applicant]
Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012; vol. …
[cited by applicant]
Johanson EK, Hollister LE, Halldin MM. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. Journal of Analytical Toxicology, 1989; p. 218-223.
[cited by applicant]
Jones RT, Benowitz N, and Bachman J. Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci. 1976; vol. 282; pp. 221-239.
[cited by applicant]
Karschner EL, Schwilke EW lowe RH et al. Implications of plasma delta-9-tetrahydrocannabinol, 11-hydroxy-THC and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol. 2009; vol. 33; pp. 469-47…
[cited by applicant]
Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992; vol. 16; pp. 228-235.
[cited by applicant]
Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007; vol. 9; pp. 413-430.
[cited by applicant]
La Porta C, Bura SA, Llorente-Onaindia J, et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015; vol. 156; pp. 2001-2012.
[cited by applicant]
Laprairie RB, Bagher, AM, Kelly, ME Denovan-Wright, EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. Oct. 2015; 172(20): 4790-4805.
[cited by applicant]
Law B, Mason PA, Moffat AC et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral Ingestion of cannabis resin. J Pharm Pharmacol. 1984; vol. 36; pp. 289-294.
[cited by applicant]
Lemberger L, Axelrod J, Kopin IJ. Metabolism and disposition of delta-9-tetrahydrocannabinol in man. Pharmacol Rev 1971; vol. 23; pp. 371-380.
[cited by applicant]
Lemberger L, Silberstein SD, Axelrod J and Kopin IJ. Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science. 2014; vol. 170; pp. 1320-1322.
[cited by applicant]
Lichtman AH, Lux EA, McQuade R, Rossetti s, Sanchez R, Sun W. Wright S, Kornyeyeva E, Fallon MT. Results of a double-blind, randomized, placebo-controlled study of Nabiximols oromucosal spray as an adjunctive therapy in…
[cited by applicant]
Lowe Rh, Abraham TT, Darwin WD et al. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009; vol. 105; pp. 24-32.
[cited by applicant]
Lucas P and Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017; vol. 42; pp. 30-35.
[cited by applicant]
Maccarrone M, Maldanado R, Casas M, Henze T, and Centonze D. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Review of Clini…
[cited by applicant]
Mackie K. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol. 2006; vol. 46; pp. 101-122.
[cited by applicant]
Maione S, Costa B, Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. 2013; vol. 154; S87-S93.
[cited by applicant]
Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016; vol. 157; S23-S32.
[cited by applicant]
Manno Je, Manno BR, Kemp PM et al. Temporal indications of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9- …
[cited by applicant]
May MB and Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to anti-emetics. Cancer Manag Res. 2016; 8: 49-55.
[cited by applicant]
McHugh D, Hu SSJ, Rimmerman N et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration trough GPR18, the putative abnormal cannabidiol receptor. Bmc Neuroscience 2010; vol…
[cited by applicant]
McPartland JM, Cannabis Systematics at the Levels of Family, Genus, and Species, Cannabis and Cannabinoid Research, vol. 3.1, 2018, p. 203-212.
[cited by applicant]
Mechoulam R and Shvo Y. Hasish. I. The structure of cannabidiol. Tetrahedron. Dec. 1963; 19(12): 2073-8.
[cited by applicant]
Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trive. Br J Pharmacol. 2005; vol. 146; pp. 913-915.
[cited by applicant]
Miller G. Pot and Pain. Hints are emerging that cannabis could be an alternative to opioid painkillers. Science. 2016, vol. 354; pp. 566-568.
[cited by applicant]
Mills M. Moguls and Mexicans: The American history of cannabis legalization. The New Econom Mar. 27, 2015. theneweconomy.com.
[cited by applicant]
Nahas GG, Greenwood A. The first report of the National Commission on marihuana (1972): signal of misunderstanding or exercise in ambiguity. Bull N Y Acad Med. Jan. 1974;50(1):55-75.
[cited by applicant]
National Cancer Institute: Common Terminology Criteria for adverse Events (CTCAE), Version 4.0 Bethesda, MD. U.S. Department of Health and Human Services, National Institutes of Health, 2010.
[cited by applicant]
National Commission on Marihuana and Drug Abuse: Marihuana: A Signal of Misunderstanding: Technical papers, Appendix, vols. 1 and 2. Washington D.C., Govt. Print. Off. 1972.
[cited by applicant]
National Governors Association Policy Academy Drug Abuse Prevention. “State of Nevada Plan to Reduce Prescription Drug Abuse”. Nevada 2017. (pp. 3-56).
[cited by applicant]
Nicholson AN, Turner C, Stone BM, and Robson PJ. Effect of delta-9 tetrahydrocannabinol and cannabidiol on nocturnal sleeep and early morning behavior in young adults. J Clin Psychopharmacol. 2004; vol. 24; pp. 305-323.
[cited by applicant]
Nutt D, King LA, Saulsbury W, and Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; vol. 369; pp. 1047-1053.
[cited by applicant]
Owens SM, McBAy AJ, Reisner HM, et al. 1251 radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method. Clin Chem. 1981; vol. 27; pp. 619-624.
[cited by applicant]
Paula-Freire Lig, Andersen ML, Molska GR, and Kohn DO. Evaluation of the Antinociceptive Activity of Ocimum gratissimumL. (Lamiaceae) Essential Oil and its isolated Active Principles in Mice. Phytother Res. 2013; vol. 2…
[cited by applicant]
Perron Be, Bohnert K, Perone AK, Bonn-Miller MO and Ilgen M. Use of prescription pain medications among medical caanbis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J St…
[cited by applicant]
Price MR, Baille GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley p. Christopoulos A, Pertwee RG, and Ross RA. Allosteric modulation of t…
[cited by applicant]
Qin N, Neeper MP, Liu Y, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008; vol. 28; pp. 6231-6238.
[cited by applicant]
Reiman et al., Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self Report; Cannabis and Cannabinoid Research, 2017, vol. 2, No. 1, p. 160-166.
[cited by applicant]
Reiter A, Hake J, Meissner C et al. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a “low-step” detoxification ward. Forensic Scilnt. 2001; vol. 119; pp. 248-253.
[cited by applicant]
Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho RC, Mcintyre RS. Drug-drug interactions as a result of co-administering A9-THC and CB…
[cited by applicant]
Russo EB. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Front Pharmacol. 2016; vol. 7, pp. 1-19.
[cited by applicant]
Russo EB. Taming THC; potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. Aug. 2011; 163 (7):1344-1364.
[cited by applicant]
Sink K, Segovia K, Sink J, et al. Potential anxiogenic effects of cannabinoid CB1 receptor anagonists/inverse agonists In rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neur…
[cited by applicant]
Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999; vol. 23; pp. 323-332.
[cited by applicant]
Solowij N, Stephens RS, Roffman RA et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAM. 2002; 287: 1123-31. Erratum in JAMA 2002; V287, No. 9. P1123-1131_1651.
[cited by applicant]
Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol. 2006; vol. 4(10); pp. 531-535.
[cited by applicant]
Svendsen KB, jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized doubleblind placebocontrolled crossover trial. BMJmj. 2004, pp. 1-9.
[cited by applicant]
Vermersch P. Sativex® (tetrahydrocannabinol + cannabidiol) and endocannabinoid system modulator: basic features and main clinical data. Expert Rev Neurother. 2011; 114 (Suppl); pp. 15-19.
[cited by applicant]
Ware MA, Wang T, Shapiro S, Collet Jpand the COMPASS study team. Cannabis for the management of pain: Asessment of safety study (Compass). J Pain; Dec. 16, 2015 (12), pp. 1233-1242.
[cited by applicant]
Wechsler H. Marihuana, alcohol and public policy. New Eng. J. Med. 287:515-17, 1972.
[cited by applicant]
Whiting PF, Wolff RE, Deshpande S, Di Niso M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Rider s, Schmidkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A systematic review and meta-analysis. J…
[cited by applicant]
Wiese et al., Emerging Evidence for Cannabis' Role in Opioid Use Disorder; Cannabis and Cannabinoid Research, 2018, vol. 3, No. 1, p. 1-11.
[cited by applicant]
Wirth PW, Watson ES, ElSohly M, et al. Anti-inflammatory properties of cannabichromene. Life Sci. 1980; vol. 26; pp. 1991-1995.
[cited by applicant]
Yamamoto I, Watanabe K Narimatsu S, and Yoshimura H. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol. 1995; vol. 27; pp. 741-746.
[cited by applicant]
Marshall, Can cannabis kill pain without getting you stoned? CU Boulder Today, Apr. 25, 2018, 3 pages.
[cited by applicant]